May 14, 2018
Atlas 5D is pleased to report that its Ambient Measurement System, Echo5D, produces similar results as two clinical gold standards of gait measurement in multiple sclerosis patients. The Echo5D allows for convenient in-home measurement. Walking speed is an important measure of gait impairment in multiple sclerosis (MS). The clinical assessment of walking speed requires dedicated time, space, and personnel, and may not accurately gauge real-world performance. The term “Ambient Measurement System” (AMS) refers to a new class of device that passively measures walking speed at home, without the need for dedicated space or specialized setup. This study compared an AMS, Echo5D, versus in-clinic standard measures of walking speed on a straight path. Twenty participants with MS and walking impairment were recruited from the Cleveland Clinic Mellen Center for MS. Each participant traversed an electronic GAITRite CIRFace (GC) sensor mat four times (two at comfortable pace, two at fast pace). Each participant then performed the Timed 25-Foot Walk (T25FW) twice, measured by a manual stopwatch (SW). All traversals were simultaneously measured by an array of Echo5D devices. Echo5D speeds were correlated with the Patient-Determined Disease Steps and the MS Walking Scale-12 patient-reported outcomes. Pearson correlations between Echo5D and clinical tests ranged from 0.89 to 0.98 (p < 0.0001). No statistically significant bias was found between Echo5D and GC. A small statistically significant bias was found between Echo5D and SW, with Echo5D reporting approximately 5% faster walking speeds in aggregate. Among MS patients with walking impairments, the Echo5D AMS acquired walking speeds which were closely correlated with the standard measures of GC and SW. The strong agreement supports the use of Echo5D to assess in-home, real-world walking performance in MS.
The results were published in Gait & Posture, March 2018, with co-authorship from Cleveland Clinic, the Massachusetts General Hospital Institute for Technology Assessment, and Atlas5D. “Walking speed measurement with an Ambient Measurement System (AMS) in patients with multiple sclerosis and walking impairment”. Francois Bethoux (Cleveland Clinic), Jonathan S. Varsanik (Atlas5D), Timothy W. Chevalier (Atlas5D), Elkan F. Halpern (MGH Institute for Technology Assessment), Darlene Stough (Cleveland Clinic), and Zebadiah M. Kimmel (Atlas5D). (2018). Gait & Posture, DOI: 10.1016/j.gaitpost.2018.01.033.
Atlas5D is a leader in creating solutions to help people with reduced mobility live better and richer lives. These populations range in age from very young to very old; cover a wide variety of conditions, such as Duchenne muscular dystrophy and multiple sclerosis; and often do not or cannot use “wearable” sensors. The company’s flagship product, Echo5D, is the first ambient sensor that passively and precisely measures human movement and behavior, 24×7, even in the dark. There’s nothing to remember, no need to wear any devices, no change in lifestyle, and no photos. By providing insight and quantitative actionable information to manufacturers, clinicians, and patients, Atlas5D offers the ability to track real-world indicators of disease status and treatment response. Please visit us at www.atlas5d.com.
is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.
GreyBird Ventures LLC (“GreyBird”) has prepared the contents of this web site (“Site”) solely for informational purposes and to assist prospective investors who view this Site (the “Recipients”) in deciding whether to proceed with a further investigation of investments managed by GreyBird. Under no circumstances shall this Site be deemed or construed to be an offer to sell, or the solicitation of an offer to buy, any securities, and it is not intended to be the basis of any investment decision or any decision to subscribe to a GreyBird investment vehicle (“Investments”). GreyBird does not make any representation or warranty, expressed or implied, as to the accuracy or completeness of information on the Site.
This Site contains certain statements and estimates made by GreyBird with respect to the anticipated future performance of its Investments and portfolio companies. Such statements and estimates reflect various assumptions concerning anticipated results, which assumptions may or may not prove to be correct. No representations or warranties are made as to the accuracy of such statements or estimates. This Site is for information only and intended for persons reasonably believed to have sufficient expertise to understand the risks involved.
Past performance is not necessarily indicative of future results, and there can be no assurance that the Investments will achieve comparable results or that GreyBird will be able to implement its strategy or achieve its investment objectives. This Site does not constitute an offer to sell or the solicitation of an offer to buy in any state or other U.S. or non-U.S. jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such state or jurisdiction. This offering does not constitute an offer of interests in the investment programs managed by GreyBird (the “Interests”) to the public, and no action has been or will be taken to permit a public offering in any jurisdiction where action would be required for that purpose. The Interests may not be offered or sold, directly or indirectly, and contents of this site may not be copied, reproduced, and/or distributed in any jurisdiction, except in accordance with the legal requirements applicable in such jurisdiction. Prospective investors should inform themselves as to the legal requirements and tax consequences within the countries of their citizenship, residence, domicile and place of business with respect to the acquisition, holding or disposal of Interests, and any non-U.S. exchange restrictions that may be relevant thereto.
Moreover, certain information contained in this Site constitutes “forward-looking” statements, which can be identified by the use of forward-looking terminology such as “may”, “will”, “seek”, “should”, “expect”, “anticipate”, “project”, “estimate”, “intend”, “continue”, “target”, or “believe” or the negatives thereof or other variations thereon or comparable terminology. Due to various risks and uncertainties, including those set forth herein, actual events or results, projected market conditions, interest rate movements, or consumer or investing trends, the actual performance of the Investments may differ materially from that which is reflected or contemplated in such forward-looking statements.
THE INTERESTS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), THE SECURITIES LAWS OF ANY STATE OR ANY OTHER APPLICABLE SECURITIES LAWS IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH LAWS. SUCH INTERESTS MUST BE ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE OFFERED FOR SALE, PLEDGED, HYPOTHECATED, SOLD, ASSIGNED OR TRANSFERRED AT ANY TIME EXCEPT IN COMPLIANCE WITH (I) THE SECURITIES ACT, ANY APPLICABLE STATE SECURITIES LAWS, AND ANY OTHER APPLICABLE SECURITIES LAWS; AND (II) THE TERMS AND CONDITIONS OF THE RELEVANT OPERATING AGREEMENT GOVERNING THE INVESTMENT. THE INTERESTS MAY NOT BE TRANSFERRED OF RECORD EXCEPT IN COMPLIANCE WITH SUCH LAWS AND SUCH OPERATING AGREEMENT. THEREFORE, PURCHASERS OF SUCH INTERESTS WILL BE REQUIRED TO BEAR THE RISK OF THEIR INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.